Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Advancing Regulatory Science

Advancing Regulatory Science

                        Regulatory Science Extramural Research and Development Projects
          Advancing Regulatory Science News and Upcoming Events
          Centers of Excellence in Regulatory Science and Innovation (CERSIs)
          Past News and Events - Advancing Regulatory Science


                        Focus Areas of Regulatory Science Report Home
          Science & Research
          Science and Research Special Topics
          Advancing Regulatory Science
          Regulatory Science Extramural Research and Development ProjectsAdvancing Regulatory Science Regulatory Science Extramural Research and Development Projects
  
  	
    Share
    Post
    Linkedin

    Email
    PrintImage
              FDA Broad Agency Announcement (BAA)

Cutting-Edge Research Funded Through FDA's Advancing Regulatory Science Broad Agency Announcement (BAA)

To spur innovation in the field of regulatory science FDA funds extramural research using various contract mechanisms and grants to address broad Agency challenges within FDA's **Regulatory Science Framework**.

Since 2012, FDA has been soliciting proposals to advance the state of the art within these areas through a specialized contract mechanism known as FDA's **Broad Agency Announcement (BAA).**FDA's BAA makes it possible for us to solicit innovative ideas and approaches to developing and evaluating FDA-regulated products by tapping into external knowledge and infrastructure in areas where FDA has limited expertise or capacities.  The proposals solicited from industry, academia, and other government agencies enable us to better understand the breath of innovative scientific and technical solutions available to solve difficult regulatory science problems.


BAA Announcement Due Dates for FY24 Funding Consideration


We have received 202 complete optional early concept papers that were submitted on time. All recommendations (Submit or Do Not Submit) have been communicated to applicants that have submitted on-time and completed optional early concept papers. Reason for Do Not Submit recommendation was predominantly lack of alignment with FDA's program priorities. Please refer the Charges and Topics in **Regulatory Science Framework**.

If you have submitted a completed optional early concept paper and not received any follow-up communication from FDA regarding a recommendation, please contact FDABAA@fda.hhs.gov.

**Charge/Topic**
			**Received**
			**Submit**
			**Do Not Submit****Total**
			**202**
			**86**
			**116****Charge I Modernize development and evaluation of FDA-regulated products**
			**145**
			**60**
			**85**A. Alternative Methods
			12
			3
			9B. Advanced Manufacturing Approaches
			59
			17
			42C. Analytical and Computational Methods
			34
			18
			16D. Biomarkers
			8
			2
			6E. Clinical Outcome Assessment
			3
			2
			1F. Complex and Novel Clinical Trial Design
			9
			4
			5G. Predictive Toxicology
			1
			1
			0H. Methods for Assessing Behavioral, Economic, or Human Factors
			4
			2
			2I. Approaches to Incorporate Patient and Consumer Input
			1
			1
			0J. Methods to Assess Real-World Data to serve as Real-World Evidence
			12
			9
			3K. Methods to Assess Data Source Interoperability
			2
			1
			1**Charge II Strengthen post-market surveillance and labeling of FDA-regulated products**
			**22**
			**11**
			**11**A. Methods to Assess Real-World Data to Support Regulatory Decision-Making
			7
			6
			1B. Using and Validating Artificial Intelligence Approaches
			5
			2
			3C. Novel Clinical Trial Design, Statistical and Epidemiologic Methods
			1
			0
			1D. Automated Reporting Tools for Adverse Events and Active Surveillance
			4
			0
			4E. Methods to Improve Communication About Risk to Patients and Consumers
			1
			0
			1F. Approach to Expand Data Capacity, and Increase Data Quality and Usen
			2
			2
			0G. Efforts to Harmonize Existing and Emerging Data Standards
			2
			1
			1**Charge III Invigorate public health preparedness and response of the FDA, patients, and consumers**
			**35**
			**15**
			**20**A. Reinforce Medical Countermeasures Initiative (MCMi)
			13
			3
			10B. Antimicrobial Resistance
			8
			2
			6C. Patient and Consumer Engagement
			3
			1
			2D. Substance Use and Misuse
			7
			6
			1E. One Health Approaches
			1
			1
			0F. Global Product Safety net
			3
			2
			1G. Emerging Technologies
			0
			0
			0



**Previous BAA Contract Awards**

FY23 BAA Contracts Awards
	FY22 BAA Contracts Awards
	FY21 BAA Contracts Awards
	FY20 BAA Contracts Awards
	FY19 BAA Contracts Awards
	FY18 BAA Contracts AwardsPast Events

January 16, 2024: FY24 FDA Broad Agency Announcement Question and Answer Session will provide an opportunity to the applicants to learn more about the application process and next steps post submission. Join us to learn more about the FY 2024 BAA and clarify any questions on how to apply and/or what to expect after submission?

October 25, 2023: FDA Broad Agency Announcement Day - FDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. Learn more about the FY 2024 BAA, and how to apply.

Resources For You

Office of Regulatory Science and Innovation

                                                                                  Content current as of:
      01/24/2024Advancing Regulatory Science

          
                        Regulatory Science Extramural Research and Development Projects
          Advancing Regulatory Science News and Upcoming Events
          Centers of Excellence in Regulatory Science and Innovation (CERSIs)
          Past News and Events - Advancing Regulatory Science


                        Focus Areas of Regulatory Science Report
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop